The SC formulations of TALVEY® (talquetamab) and DARZALEX® (daratumumab) exhibit significant and lasting effects in relapsed or refractory multiple myeloma patients.
The FDA has given the green light to Bristol Myers Squibb's COBENFY™ (xanomeline and trospium chloride), a unique muscarinic agonist for adult schizophrenia treatment.
Sage Therapeutics, Inc. (NASDAQ: Sage) disclosed that Biogen has relinquished its rights under the collaboration and license deal with Sage concerning the SAGE-324 program.
Sep 28th latest updates in the global new drug development field, including progress in new drug research and development, transaction information, and partnership developments.